Table 3.

Multivariable Poisson regression of number of anti-VEGF injections over the first 6 months after the index date

Variables	Count ratio	95% CI	P-value	Level
(Intercept)	0.90	(0.22–3.62)	0.884
Anti-VEGF medication (aflibercept)	1.02	(0.95–1.10)	0.525
Sex (female)	1.04	(0.97–1.10)	0.265
Age group, years (19–25)
26–30	1.00	(0.14–7.10)	1.00
31–35	2.41	(0.52–11.16)	0.262
36–40	3.12	(0.66–14.71)	0.151
41–45	3.92	(0.93–16.53)	0.063	*
46–50	4.58	(1.10–18.98)	0.036	**
51–55	4.08	(1.00–16.69)	0.050	*
56–60	4.51	(1.12–18.20)	0.035	**
61–65	4.54	(1.13–18.25)	0.033	**
66–70	4.54	(1.13–18.25)	0.033	**
71–75	4.31	(1.07–17.28)	0.039	**
76–80	4.18	(1.04–16.75)	0.044	**
81–85	4.21	(1.05–16.89)	0.042	**
86–90	4.00	(1.00–16.05)	0.050	*
≥91	3.47	(0.86–13.97)	0.080	*
Region (Geneva Lake)
Middle land	0.97	(0.87–1.08)	0.585
Northwest	0.97	(0.86–1.08)	0.541
East	1.06	(0.94–1.20)	0.350
South (Tessin)	0.81	(0.70–0.93)	0.003	***
Central	1.08	(0.95–1.24)	0.241
Zurich	1.06	(0.96–1.17)	0.269

Notes:

^*P<0.10,

^**P<0.05,

^***P<0.01.

Abbreviations: CI, confidence interval; VEGF, vascular endothelial growth factor.